Brief: NewAmsterdam Pharma Enrolls Over 9,000 Patients In Late-Stage Global Cardiovascular Outcome Trial
09/04/2024 14:41
April 9 (Reuters) - NewAmsterdam Pharma Company NV
KH6.F :
* NEWAMSTERDAM PHARMA ENROLLS OVER 9,000 PATIENTS IN PIVOTAL
PHASE
3 PREVAIL GLOBAL CARDIOVASCULAR OUTCOME TRIAL EVALUATING THE
EFFECT OF OBICETRAPIB IN PATIENTS WITH ESTABLISHED
ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
* NEWAMSTERDAM PHARMA: WITH PREVAIL CVOT ENROLLMENT TARGET
MET,
TOPLINE DATA FROM BROOKLYN & BROADWAY EXPECTED IN Q3, Q4 2024,
AND TANDEM IN Q1 2025
Source text for Eikon: ID:nGNXBQWdZ
Further company coverage: KH6.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NewAmsterdam Pharma
See all newsBrief: Menarini Group & Newamsterdam Pharma Receive European Commission Approval For Ubeslo And Evlarco
Amgen falls after Novartis trial setback, BMO downgrade
Brief: Newamsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Newamsterdam Pharma Company N.V. - Announces Positive CHMP Opinion For Obicetrapib And Obicetrapib/Ezetimibe
Brief: NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)